ROHTO PHARMACEUTICAL CO.,LTD.
4527・Prime Market・Pharmaceuticals
ROHTO PHARMACEUTICAL CO.,LTD.4527
ROHTO PHARMACEUTICAL CO.,LTD.4527
Reference Indicators
Market Cap
5,751¥100M
P/E (Forecast)
15.9x
P/B
1.8x
Dividend Yield (Forecast)
2.05%
ROE
12.1%
EV/EBITDA
8.8x
Financial Summary
Unit: ¥M
| Item | 2022Mar 2022 | 2023Mar 2023 | 2024Mar 2024 | 2025Mar 2025 | 2026Mar 2026 |
|---|---|---|---|---|---|
Net Sales | 199,646 | 238,664 | 270,840 | 308,625 | 343,725 |
Cost of Sales | 83,157 | 101,243 | 113,554 | 133,686 | 151,030 |
Gross Profit | 116,488 | 137,421 | 157,285 | 174,939 | 192,695 |
SG&A Expenses | 87,139 | 103,461 | 117,237 | 135,999 | 151,576 |
Operating Income | 29,349 | 33,959 | 40,048 | 38,939 | 41,118 |
Non-operating Income | 1,580 | 3,697 | 3,547 | 3,507 | 9,009 |
Non-operating Expenses | 1,844 | 2,089 | 1,161 | 2,016 | 2,155 |
Ordinary Income | 29,084 | 35,568 | 42,434 | 40,430 | 47,971 |
Extraordinary Income | 636 | 360 | 230 | 4,151 | 337 |
Extraordinary Losses | 1,767 | 1,639 | 1,146 | 2,251 | 1,486 |
Pre-tax Income | 27,953 | 34,290 | 41,518 | 42,331 | 46,821 |
Income Taxes | 6,803 | 7,860 | 10,123 | 11,379 | 12,404 |
Net Income | 21,018 | 26,377 | 30,936 | 31,006 | 34,247 |
EBITDA | 37,022 | 41,760 | 48,735 | 52,082 | 58,495 |
Gross Margin | 58.3% | 57.6% | 58.1% | 56.7% | 56.1% |
Operating Margin | 14.7% | 14.2% | 14.8% | 12.6% | 12.0% |
ROA | 7.7% | 8.5% | 8.9% | 7.3% | 7.0% |
ROE | 12.6% | 13.6% | 13.6% | 12.3% | 12.1% |
Segment Performance
Unit: ¥M
2026
| Segment | Net Sales | Operating Income | Operating Margin |
|---|---|---|---|
| 日本 | 169,326 | 22,126 | 13.1% |
| アメリカ | 21,553 | 1,705 | 7.9% |
| ヨーロッパ | 23,889 | 1,007 | 4.2% |
| アジア | 125,327 | 15,048 | 12.0% |
| その他 | 3,628 | 383 | 10.6% |